HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nutrition & Obesity Medicine
Meta-analysis
Semaglutide associated with 35.2% of weight loss as lean mass versus 26.2% with lifestyle interventions
New analysis shows weight loss drugs and lifestyle changes affect muscle loss similarly
This systematic review and meta-analysis evaluated 15 782 adults with overweight or obesity receiving incretin-based therapies or intensive …
A large review of 15,782 adults found that weight loss drugs and lifestyle changes led to similar proportions of muscle loss during weight r…
Jun 6, 2026
Nutrition & Obesity Medicine
Sys. Review
Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
New analysis shows weight loss drugs work best for adults with obesity without diabetes
This systematic review and network meta-analysis of 14,059 adults with obesity without diabetes ranked GLP-1 receptor agonists and a dual ag…
A large review of many studies found that specific injectable medicines help adults lose weight. Tirzepatide worked best, but all options re…
Jun 4, 2026
Diabetes & Endocrinology
Meta-analysis
GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
New analysis shows GLP-1 drugs cut stroke risk for people with leg artery disease
This systematic review and meta-analysis of over 240,000 adults with peripheral artery disease found that GLP-1 receptor agonists significan…
A large review of real-world data found GLP-1 drugs significantly reduce stroke and heart attack risk in adults with peripheral artery disea…
Jun 1, 2026
Diabetes & Endocrinology
RCT
Tirzepatide improves waist-to-height ratio in adults with obesity or overweight
Tirzepatide improves waist-to-height ratio in obesity and prediabetes
A post-hoc analysis of a Phase 3 RCT found that tirzepatide (10/15 mg) improved waist-to-height ratio (WHtR) in adults with obesity or overw…
A new analysis finds tirzepatide helps more people with obesity achieve a healthier waist-to-height ratio, a key measure of belly fat risk.
Jun 1, 2026
Diabetes & Endocrinology
Meta-analysis
Systematic review and meta-analysis of tirzepatide effects on HbA1c and weight in adults with type 2 diabetes
Tirzepatide lowers blood sugar and weight in real-world diabetes care
This systematic review and meta-analysis pooled data from real-world studies involving 89 296 adults with type 2 diabetes. Tirzepatide was a…
A large review of real-world data shows tirzepatide lowers blood sugar and helps people lose weight, matching results from clinical trials.
May 26, 2026
Diabetes & Endocrinology
Meta-analysis
Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
New Weight Loss Drug Beats Popular Options in Head-to-Head Comparison
This Bayesian network meta-analysis synthesized evidence from 42 randomized controlled trials, six of which were included in the network, to…
A newer weight loss drug helped people drop nearly 14 percent of their body weight, beating two popular options in a major comparison.
May 8, 2026
Diabetes & Endocrinology
Meta-analysis
Network Meta-Analysis Finds Tirzepatide and Sleeve Gastrectomy Equally Effective for Weight Loss in Obesity
New Weight Loss Pill Matches Surgery Results Without the Scalpel
A network meta-analysis of 14,293 adults with obesity found that tirzepatide 10 or 15 mg and sleeve gastrectomy achieved similar weight loss…
A diabetes drug now pulls even with stomach surgery for weight loss offering hope to millions who dread going under the knife but it is not …
May 4, 2026
Diabetes & Endocrinology
Meta-analysis
CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA
CPAP and weight-loss drugs show different benefits for sleep apnea patients
This network meta-analysis of 3964 adults with obstructive sleep apnea found that CPAP produced the largest reduction in apnea-hypopnea inde…
A large analysis found CPAP best for breathing control, while weight-loss drugs improved body weight and blood sugar levels in sleep apnea p…
May 1, 2026
Drug Pipeline
RCT
Tirzepatide improves standard and intensive therapeutic target attainment versus semaglutide in adults with type 2 diabetes
New drug helps more patients hit four key health goals at once
This post hoc analysis of a randomised phase 3 study included 1879 adults with type 2 diabetes followed for 40 weeks.
A new diabetes medicine helps more people hit their blood sugar, weight, and blood pressure goals at the same time
May 1, 2026
Diabetes & Endocrinology
Meta-analysis
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
May 1, 2026
Diabetes & Endocrinology
Meta-analysis
Network Meta-Analysis Finds Tirzepatide and Semaglutide Most Effective for Weight Loss in Adults
New Weight Loss Drugs Protect Your Heart and Lower Death Risk
A systematic review and network meta-analysis of 63,909 adults found that all obesity medications produced greater weight loss than placebo.
New data from 66 trials shows top obesity drugs significantly reduce heart events and death while helping with liver and joint pain issues f…
medRxiv
Apr 24, 2026
Oncology
Review of observational data links semaglutide and tirzepatide to survival in breast cancer
Semaglutide linked to lower death rates in breast cancer patients compared to other diabetes drugs
This review synthesized observational, propensity-matched analyses of patients with pre-existing breast cancer.
In routine care, semaglutide users with breast cancer had significantly lower death rates and less metastatic disease than those on other co…
medRxiv
Apr 24, 2026